Fandozzi Christine, Evans Christopher, Wilson Amanda, Su Dian, Anderson Melanie, Clausen Valerie, Dillen Lieve, Garofolo Fabio, Holliman Chris, Nickbarg Elliott, Olah Timothy, Ramanathan Ragu, Zhang Hui, Kaur Surinder, Pillutla Renuka, Yu Hongbin, Bateman Kevin, Donato Lorella Di, Hengel Shawna, Jian Wenying, Jones Barry, Kellie John, Lee Anita, Palandra Joe, Savoie Natasha, Shipkova Petia, Spitz Susan, Su Dian, Szapacs Matthew, Wang Jian, Wright Katherine, Zeng Jianing
Merck, West Point, PA, USA.
GlaxoSmithKline, Collegeville, PA, USA.
Bioanalysis. 2019 Nov;11(22):2029-2048. doi: 10.4155/bio-2019-0260. Epub 2019 Dec 6.
The 2019 13 Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA, USA on April 1-5, 2019 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event - a full immersion week of bioanalysis, biomarkers, immunogenicity and gene therapy. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small- and large-molecule bioanalysis involving LCMS, hybrid LBA/LCMS, LBA cell-based/flow cytometry assays and qPCR approaches. This 2019 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2019 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1) covers the recommendations on Innovation in Small Molecules and Oligonucleotides & Mass Spec Method Development Strategies for Large Molecules Bioanalysis. Part 2 (2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and regulatory agencies' input on bioanalysis, biomarkers, immunogenicity and gene therapy) and Part 3 (New Insights in Biomarkers Assays Validation, Current & Effective Strategies for Critical Reagent Management, Flow Cytometry Validation in drug discovery & development & CLSI H62, Interpretation of the 2019 FDA Immunogenicity Guidance and The Gene Therapy Bioanalytical Challenges) are published in volume 11 of , issues 23 and 24 (2019), respectively.
2019年生物分析近期问题研讨会(WRIB)于2019年4月1日至5日在美国路易斯安那州新奥尔良市举行,来自全球制药/生物制药公司、生物技术公司、合同研究组织和监管机构的1000多名代表出席了会议。WRIB再次成为为期5天、长达一周的活动——一个全面沉浸于生物分析、生物标志物、免疫原性和基因治疗的一周。像往常一样,它的特别设计旨在促进就解决当前最受关注问题的方法进行分享、审查、讨论并达成共识,这些问题包括涉及液相色谱 - 质谱联用(LCMS)、混合配体结合分析/液相色谱 - 质谱联用(LBA/LCMS)、基于细胞的配体结合分析/流式细胞术检测以及定量聚合酶链反应(qPCR)方法的小分子和大分子生物分析。这份2019年白皮书涵盖了研讨会期间广泛讨论产生的建议,旨在为生物分析界提供关于所涉及主题和问题的关键信息及实际解决方案,以推动科学卓越性的进步、提高质量并更好地符合法规要求。由于篇幅原因,这份全面白皮书的2019年版出于编辑目的分为三个部分。本出版物(第1部分)涵盖了小分子和寡核苷酸创新以及大分子生物分析的质谱方法开发策略方面的建议。第2部分(2018年美国食品药品监督管理局生物分析方法验证指南、2019年国际人用药品注册技术协调会M10生物分析方法验证草案指南以及监管机构对生物分析、生物标志物、免疫原性和基因治疗的意见)和第3部分(生物标志物检测验证的新见解、关键试剂管理的当前及有效策略、药物发现与开发中的流式细胞术验证及临床和实验室标准协会H62、2019年美国食品药品监督管理局免疫原性指南解读以及基因治疗生物分析挑战)分别发表于《[期刊名称]》第11卷第23期和第24期(2019年)。